
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
The National Institute of Child Health and Human Development (NICHD) has announced plans to conduct a large-scale study to determine which of the two most commonly-prescribed medications; diazepam (Valium) or lorazepam (Ativan), is the safer and more effective treatment for children with status epilepticus [more].






